Financial Architects, Inc Clovis Oncology, Inc. Transaction History

Financial Architects, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$12.81 - $25.67 $5,764 - $11,551	-450 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$17.66 - $30.28 $7,947 - $13,626	450 New	450 $11,000
Q1 2019 May 03, 2019	SELL	$17.66 - $30.28 $7,947 - $13,626	-450 Closed	0 $0
Q1 2018 Apr 23, 2018	BUY	$50.12 - $67.72 $17,542 - $23,702	350 Added 350.0%	450 $24,000
Q4 2017 Feb 12, 2018	BUY	$57.69 - $84.58 $5,769 - $8,458	100	100 $7,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.